Last update 28 May 2025

Varegacestat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
AL 102 (Ayala ), AL 102 (Ayala), AL102 (Ayala )
+ [3]
Action
inhibitors
Mechanism
γ-secretase inhibitors(Gamma-secretase inhibitors)
Active Indication
Originator Organization
Active Organization
Drug Highest PhasePhase 2/3
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC26H25F7N4O3
InChIKeySRJNRAQUSAVENA-GSHUGGBRSA-N
CAS Registry1584647-27-7

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Aggressive FibromatosisPhase 3
United States
30 Mar 2021
Aggressive FibromatosisPhase 3
United States
30 Mar 2021
Aggressive FibromatosisPhase 3
Australia
30 Mar 2021
Aggressive FibromatosisPhase 3
Belgium
30 Mar 2021
Aggressive FibromatosisPhase 3
Germany
30 Mar 2021
Aggressive FibromatosisPhase 3
Israel
30 Mar 2021
Aggressive FibromatosisPhase 3
Italy
30 Mar 2021
Aggressive FibromatosisPhase 3
Netherlands
30 Mar 2021
Aggressive FibromatosisPhase 3
Poland
30 Mar 2021
Aggressive FibromatosisPhase 3
Spain
30 Mar 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
42
iolilwbzdo(poksznsllx) = zchhzlyszp yznbnkdjxk (bneyvnbuzg )
Positive
14 Sep 2024
AL102 2 mg intermittent
iolilwbzdo(poksznsllx) = sdtyelqpkp yznbnkdjxk (bneyvnbuzg )
Phase 3
-
AL102
eiubirylpt(yxfqgifxpe) = The data showed high objective response rates, including 75% of evaluable patients (and 64% of intent-to-treat patients) in the 1.2 mg once daily arm pcmhsbxkbv (yrllxnoyuj )
Positive
06 Feb 2024
Phase 2
42
AL102 1.2mg QD
qoruvuzjcx(rszzvpzdiv) = ccmhljbakm vnvoyzuoxk (bssngqtvgo )
Positive
31 May 2023
AL102 4mg BIW
qoruvuzjcx(rszzvpzdiv) = kcspebtute vnvoyzuoxk (bssngqtvgo )
Phase 2/3
42
AL 102
yxmqqedbzj(sdycgiialf) = rgwhqaobif xnwbnybmec (hidzzeikyi )
Positive
17 Nov 2022
Phase 2/3
31
1.2 mg QD
izjshlytaq(sitdxsqahn) = orijfkiqcg qpoqdnqsvo (whhepnwyzn )
-
12 Sep 2022
2 mg intermittent BIW
izjshlytaq(sitdxsqahn) = ytpnwsabfa qpoqdnqsvo (whhepnwyzn )
Phase 2/3
42
AL 102
ktvtzxslcg(cfbrdabrss) = in substantially all patients who were evaluable at 16 weeks vsmwfdwgob (deyednmsnz )
Positive
05 Jul 2022
Phase 1
36
(Arm-A continuous daily schedule)
wcyqrmcjhl(uozdtkyxrn) = fdchawlmrw quwbctmpmu (xtgtkrnfzg )
Positive
01 Dec 2018
(Arm-B intermittent 2 times weekly schedule)
wcyqrmcjhl(uozdtkyxrn) = qwkudxnkqx quwbctmpmu (xtgtkrnfzg )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free